|
1
|
Banerji B, Pramanik SK, Pal U and Maiti
NC: Potent anticancer activity of cystine-based dipeptides and
their interaction with serum albumins. Chem Cent J. 7:912013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Misale S, Yaeger R, Hobor S, Scala E,
Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M,
Siravegna G, et al: Emergence of KRAS mutations and acquired
resistance to anti-EGFR therapy in colorectal cancer. Nature.
486:532–536. 2012.PubMed/NCBI
|
|
3
|
Diaz LA Jr, Williams RT, Wu J, Kinde I,
Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al:
The molecular evolution of acquired resistance to targeted EGFR
blockade in colorectal cancers. Nature. 486:4–7. 2012.
|
|
4
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boutros T, Chevet E and Metrakos P:
Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase
regulation: Roles in cell growth, death, and cancer. Pharmacol Rev.
60:261–310. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kyriakis JM and Avruch J: Mammalian MAPK
signal transduction pathways activated by stress and inflammation:
A 10-year update. Physiol Rev. 92:689–737. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cargnello M and Roux PP: Activation and
function of the MAPKs and their substrates, the MAPK-activated
protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Samatar AA and Poulikakos PI: Targeting
RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug
Discov. 13:928–942. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Igea A and Nebreda AR: The stress kinase
p38α as a target for cancer therapy. Cancer Res. 75:3997–4002.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koul HK, Pal M and Koul S: Role of p38 MAP
kinase signal transduction in solid tumors. Genes Cancer.
4:342–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tournier C: The 2 faces of JNK signaling
in cancer. Genes Cancer. 4:397–400. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hoesel B and Schmid JA: The complexity of
NF-κB signaling in inflammation and cancer. Mol Cancer. 12:862013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gyrd-Hansen M and Meier P: IAPs: From
caspase inhibitors to modulators of NF-kappaB, inflammation and
cancer. Nat Rev Cancer. 10:561–574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sung B, Prasad S, Yadav VR and Aggarwal
BB: Cancer cell signaling pathways targeted by spice-derived
nutraceuticals. Nutr Cancer. 64:173–197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Erstad DJ, Cusack JC Jr, et al: Targeting
the NF-κB pathway in cancer therapy. Surg Oncol Clin N Am.
22:705–746. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gilmore TD: Introduction to NF-kappaB:
Players, pathways, perspectives. Oncogene. 25:6680–6684. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Santos DM, Verly RM, Piló-Veloso D, de
Maria M, de Carvalho MA, Cisalpino PS, Soares BM, Diniz CG, Farias
LM, Moreira DF, et al: LyeTx I, a potent antimicrobial peptide from
the venom of the spider Lycosa erythrognatha. Amino Acids.
39:135–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Correa CR, Bertollo CM and Goes AM:
Establishment and characterization of MACL-1 and MGSO-3 cell lines
derived from human primary breast cancer. Oncol Res. 17:473–482.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pierce JW, Schoenleber R, Jesmok G, Best
J, Moore SA, Collins T and Gerritsen ME: Novel inhibitors of
cytokine-induced IkappaBalpha phosphorylation and endothelial cell
adhesion molecule expression show anti-inflammatory effects in
vivo. J Biol Chem. 272:21096–21103. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bain J, Plater L, Elliott M, Shpiro N,
Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR and
Cohen P: The selectivity of protein kinase inhibitors: A further
update. Biochem J. 408:297–315. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Clark K, Nanda S and Cohen P: Molecular
control of the NEMO family of ubiquitin-binding proteins. Nat Rev
Mol Cell Biol. 14:673–685. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martin SE, Wu ZH, Gehlhaus K, Jones TL,
Zhang YW, Guha R, Miyamoto S, Pommier Y and Caplen NJ: RNAi
screening identifies TAK1 as a potential target for the enhanced
efficacy of topoisomerase inhibitors. Curr Cancer Drug Targets.
11:976–986. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Safina A, Ren MQ, Vandette E and Bakin AV:
TAK1 is required for TGF-beta 1-mediated regulation of matrix
metalloproteinase-9 and metastasis. Oncogene. 27:1198–1207. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen L, Mayer JA, Krisko TI, Speers CW,
Wang T, Hilsenbeck SG and Brown PH: Inhibition of the p38 kinase
suppresses the proliferation of human ER-negative breast cancer
cells. Cancer Res. 69:8853–8861. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leelahavanichkul K, Amornphimoltham P,
Molinolo AA, Basile JR, Koontongkaew S and Gutkind JS: A role for
p38 MAPK in head and neck cancer cell growth and tumor-induced
angiogenesis and lymphangiogenesis. Mol Oncol. 8:105–118. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kummer JL, Rao PK and Heidenreich KA:
Apoptosis induced by withdrawal of trophic factors is mediated by
p38 mitogen-activated protein kinase. J Biol Chem. 272:20490–20494.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bulavin DV, Kovalsky O, Hollander MC,
Fornace AJ Jr, et al: Loss of oncogenic H-ras-induced cell cycle
arrest and p38 mitogen-activated protein kinase activation by
disruption of Gadd45a. Mol Cell Biol. 23:3859–3871. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
She QB, Bode AM, Ma WY, Chen NY and Dong
Z: Resveratrol-induced activation of p53 and apoptosis is mediated
by extracellular-signal-regulated protein kinases and p38 kinase.
Cancer Res. 61:1604–1610. 2001.PubMed/NCBI
|
|
31
|
Mikhailov A, Shinohara M and Rieder CL:
Topoisomerase II and histone deacetylase inhibitors delay the G2/M
transition by triggering the p38 MAPK checkpoint pathway. J Cell
Biol. 166:517–526. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bulavin DV, Amundson SA and Fornace AJ:
p38 and Chk1 kinases: Different conductors for the G(2)/M
checkpoint symphony. Curr Opin Genet Dev. 12:92–97. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thornton TM and Rincon M: Non-classical
p38 map kinase functions: Cell cycle checkpoints and survival. Int
J Biol Sci. 5:44–51. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huth HW, Albarnaz JD, Torres AA, Bonjardim
CA and Ropert C: MEK2 controls the activation of MKK3/MKK6-p38 axis
involved in the MDA-MB-231 breast cancer cell survival: Correlation
with cyclin D1 expression. Cell Signal. 28:1283–1291. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schieven GL: The biology of p38 kinase: A
central role in inflammation. Curr Top Med Chem. 5:921–928. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
del Barco Barrantes I and Nebreda AR:
Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans.
40:79–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pal S, Bhattacharjee A, Ali A, Mandal NC,
Mandal SC and Pal M: Chronic inflammation and cancer: potential
chemoprevention through nuclear factor kappa B and p53 mutual
antagonism. J Inflamm (Lond). 11:232014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee ST, Li Z, Wu Z, Aau M, Guan P,
Karuturi RKM, Liou YC and Yu Q: Context-specific regulation of
NF-κB target gene expression by EZH2 in breast cancers. Mol Cell.
43:798–810. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Han R, Liang H, Qin ZH and Liu CY:
Crotoxin induces apoptosis and autophagy in human lung carcinoma
cells in vitro via activation of the p38MAPK signaling pathway.
Acta Pharmacol Sin. 35:1323–1332. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu Z, Zhao Y, Li J, Xu S, Liu C, Zhu Y
and Liang S: The venom of the spider Macrothele raveni induces
apoptosis in the myelogenous leukemia K562 cell line. Leuk Res.
36:1063–1066. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ninomiya-Tsuji J, Kishimoto K, Hiyama A,
Inoue J, Cao Z and Matsumoto K: The kinase TAK1 can activate the
NIK-I kappaB as well as the MAP kinase cascade in the IL-1
signalling pathway. Nature. 398:252–256. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
McDermott EP and O'Neill LA: Ras
participates in the activation of p38 MAPK by interleukin-1 by
associating with IRAK, IRAK2, TRAF6, and TAK-1. J Biol Chem.
277:7808–7815. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mihaly SR, Ninomiya-Tsuji J and Morioka S:
TAK1 control of cell death. Cell Death Differ. 21:1667–1676. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sakurai H: Targeting of TAK1 in
inflammatory disorders and cancer. Trends Pharmacol Sci.
33:522–530. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kabir MH, Suh EJ and Lee C: Comparative
phosphoproteome analysis reveals more ERK activation in MDA-MB-231
than in MCF-7. Int J Mass Spectrom. 309:1–12. 2012. View Article : Google Scholar
|
